

13 Part VI: Summary of the risk management plan for Lacosamide, 50 mg, 100 mg, 150 mg and 200 mg, Film-coated tablets

This is a summary of the risk management plan (RMP) for lacosamide, 50 mg, 100 mg, 150 mg and 200 mg, film-coated tablets. The RMP details important risks of lacosamide, film-coated tablets, how these risks can be minimized and how more information will be obtained about lacosamide, film-coated tablets' risks and uncertainties (missing information).

Lacosamide, film-coated tablets' summary of product characteristics (SmPC) and its package leaflet (PL) give essential information to healthcare professionals (HCPs) and patients on how lacosamide, film-coated tablets should be used.

Important new concerns or changes to the current ones will be included in updates of the lacosamide, film-coated tablets' RMP.

13.1 Part VI: I. The medicine and what it is used for

Lacosamide, film-coated tablets are authorized for:

Lacosamide is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalization in adults, adolescents and children from 4 years of age with epilepsy.

Lacosamide is indicated as adjunctive therapy

- In the treatment of partial-onset seizures with or without secondary generalization in adults, adolescents and children from 4 years of age with epilepsy.
- In the treatment of primary generalized tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalized epilepsy.

It contains lacosamide as an active substance and is given orally as film-coated tablets (50 mg, 100 mg, 150 mg and 200 mg).

13.2 Part VI: II. Risks associated with the medicine and activities to minimize or further characterize the risks

Important risks of lacosamide, film-coated tablets, together with measures to minimize such risks and the proposed studies for learning more about lacosamide, film-coated tablets risks are outlined below.

Measures to minimize the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the PL and SmPC addressed to patients and HCPs;
- Important advice on the medicine's packaging;
- The authorized pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status — the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimize its risks.

Together, these measures constitute *routine risk minimization* measures.

In addition to these measures, information about adverse reactions is collected continuously and regularly analyzed, including Periodic Safety Update Report (PSUR) assessment (if applicable) so that immediate action can be taken as necessary. These measures constitute *routine pharmacovigilance activities*.

If important information that may affect the safe use of lacosamide, film-coated tablets is not yet available, it is listed under ‘missing information’ below.

13.2.1 Part VI – II.A: List of important risks and missing information

Important risks of lacosamide, film-coated tablets are risks that need special risk management activities to further investigate or minimize the risk, so that the medicinal product can be safely taken. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of lacosamide, film-coated tablets. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine).

Table 13-1 List of important risks and missing information

| List of important risks and missing information | |
|---|---|
| Important identified risks | Cardiac adverse events (AEs) that may be potentially associated with PR interval prolongation and sodium channel modulation |
| Important potential risks | None |
| Missing information | Pregnant or lactating women |
| | Impact on long-term growth, long-term neurodevelopment, and on puberty in pediatric population aged 4 to < 16 years |

13.2.2 Part VI – II.B: Summary of important risks

The safety information in the proposed Product Information is aligned to the reference medicinal product.

13.2.3 Part VI – II.C: Post-authorization development plan

13.2.3.1 II.C.1 Studies which are conditions of the marketing authorization

There are no studies which are conditions of the marketing authorization or specific obligation of lacosamide, film-coated tablets.

13.2.3.2 II.C.2. Other studies in post-authorization development plan

There are no studies required for lacosamide, film-coated tablets.